Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 740-746

  Hahn, Margaret Karolina ^a,b   Wolever, Tom M S ^c,d   Arenovich, Tamara ^a   Teo, Celine ^a   Giacca, Adria ^a,d   Powell, Valerie ^a   Clarke, Leigh ^a   Fletcher, Paul ^a,d   Cohn, Tony ^a,c,e   McIntyre, Roger S ^b,e,f   Gomes, Sylvia ^a   Chintoh, Araba ^a   Remington, Gary J ^a,b,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Department of Physiology ^*  (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

atypical antipsychotics; diabetes; glucose metabolism,cytokines; olanzapine; schizophrenia

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; FATTY ACID; GLUCOSE; HYDROCORTISONE; INTERLEUKIN 6; MARKER; OLANZAPINE; PLACEBO; PROLACTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOGLYCEMIA; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID METABOLISM; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE;

ADIPOKINES; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PROLACTIN;

EID: 84888137371     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829e8333     Document Type: Article

References (50)

1. Emsley R, Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2004;7:219-238.
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
3. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150: 1115-1121.
4. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64-66.
5. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
6. Chintoh AF, Mann SW, Lam L, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108:127-133.
7. Boyda HN, Tse L, Procyshyn RM, et al. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci. 2010;31:484-497.
8. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25:255-258.
9. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-871.
10. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, et al. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95:118-125.
11. Vidarsdottir S, Vlug P, Roelfsema F, et al. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry. 2010;71:1205-1211.
12. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology. 2008;33:1633-1641.
13. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003;88:5875-5880.
14. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918-2923.
15. Fountaine RJ, Taylor AE, Mancuso JP, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18:1646-1651.
16. Albaugh VL, Singareddy R, Mauger D, et al. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6:e22662.
17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237:E214-223.
18. Bergman RN, Prager R, Volund A, et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 1987;79:790-800.
19. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(suppl 1):S37-S42.
20. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-1395.
21. Finegood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 1990;70:1538-1549.
22. Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 2006;46:164-171.
23. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66:504-514.
24. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest. 2002;32(suppl 3):35-45.
25. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev. 2001;22:565-604.
26. Ohnuma H, Yamatani K, Igarashi M, et al. Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats. J Auton Nerv Syst. 1996;57:43-48.
27. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27: 289-304.
28. Hucking K, Watanabe RM, Stefanovski D, et al. OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity (Silver Spring). 2008;16:1938-1945.
29. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry. 2009;70:765-766.
30. Kapur S, VanderSpek SC, Brownlee BA, et al. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305:625-631.
31. Best JD, Kahn SE, Ader M, et al. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care. 1996;19:1018-1030.
32. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
33. Hardy TA, Henry RR, Forrester TD, et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes Metab. 2011;13:726-735.
34. Cohrs S, Roher C, Jordan W, et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl). 2006;185:11-18.
35. Meyer G, Badenhoop K. Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin. 2003;98: 266-270.
36. Samra JS, Clark ML, Humphreys SM, et al. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab. 1998;83:626-631.
37. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007;32: 765-772.
38. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med. 2008;14:741-751.
39. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24:481-485.
40. Fernandez-Egea E, Bernardo M, Donner T, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009;194:434-438.
41. Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382-386.
42. Caspersen CJ, Pereira MA, Curran KM. Changes in physical activity patterns in the United States, by sex and cross-sectional age. Med Sci Sports Exerc. 2000;32:1601-1609.
43. Kahn SE, Larson VG, Beard JC, et al. Effect of exercise on insulin action, glucose tolerance, and insulin secretion in aging. Am J Physiol. 1990;258:E937-E943.
44. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534-539.
45. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
46. Makhzoumi ZH, McLean LP, Lee JH, et al. Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy. 2008;28:1198-1202.
47. Dhamija R, Verma R. Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. Diabetes Care. 2008;31:e50.
48. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry. 2002;159:1435.
49. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
50. Agid O, Foussias G, Singh S, et al. Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55:677-684.